An all-outdoor cultivator and manufacturer of global cannabis products and brands, announced on Wednesday that it wants approval from INVIMA (the Colombian FDA) to begin research on its patent-pending, cannabinoid-based product to combat the SARS-CoV-2 (COVID-19) virus.
Citing recent studies stating the possibility of cannabinoids to display viral inhibition,
Flora Growth Corp. (NASDAQ: FLGC, Forum) believes that breakthrough research intends to explore a preventative application against COVID for the patent-pending cannabinoid formulation.
This diverse study will be conducted through Flora’s research division, Flora Pharma, with formulation taking place in its GMP-certified Colombian lab. The research will look at all of the potential mechanisms of cannabinoids in preventing infection from COVID-19.
The head of Flora Pharma, Dr. Annabelle Manalo-Morgan has spent the last five years researching cannabis and has specialized in the formulation of cannabinoid products for clinical trials since the pandemic began.
“The intent of the study is to identify safe and efficacious cannabinoid products for use on SARS-CoV-2 thus allowing us to pursue the fastest path to market via a preventative immunomodulating product and to explore the possibility of use as a therapeutic. I believe the Flora team is best positioned to formulate, test and ultimately bring to the market this kind of novel product offering.”
President and CEO of Flora Growth, Luis Merchan said in
a media release on this news that the team is excited to begin the research process.
“The Flora Pharma division seeks to obtain evidence to support this product's use against SARS-CoV-2 and bring to market an effective, cannabinoid-based product.”
If approved, Flora’s formulation would be the first product containing cannabinoids approved by the Colombian government for use against COVID.